Agile Therapeutics, Inc.
Agile Therapeutics, Inc. (AGRX) Stock Competitors & Peer Comparison
See (AGRX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AGRX | $1.51 | +3.42% | 10.4M | -0.89 | -$1.70 | N/A |
| ZTS | $151.01 | +0.17% | 67.2B | 27.11 | $5.57 | +1.28% |
| TAK | $14.32 | +0.07% | 45.2B | 62.24 | $0.23 | +4.11% |
| HLN | $9.81 | +1.13% | 44.2B | 22.81 | $0.43 | +1.72% |
| TEVA | $16.54 | +0.18% | 19B | -14.39 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $134.19 | +0.36% | 13.3B | 45.49 | $2.95 | N/A |
| RDY | $14.76 | +0.41% | 12.3B | 18.68 | $0.79 | +0.50% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.19 | -0.76% | 10.8B | -2.89 | -$3.18 | +5.21% |
Stock Comparison
AGRX vs ZTS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ZTS has a market cap of 67.2B. Regarding current trading prices, AGRX is priced at $1.51, while ZTS trades at $151.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZTS's P/E ratio is 27.11. In terms of profitability, AGRX's ROE is +0.93%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, AGRX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ZTS's competition here
AGRX vs TAK Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TAK has a market cap of 45.2B. Regarding current trading prices, AGRX is priced at $1.51, while TAK trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TAK's P/E ratio is 62.24. In terms of profitability, AGRX's ROE is +0.93%, compared to TAK's ROE of +0.04%. Regarding short-term risk, AGRX is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check TAK's competition here
AGRX vs HLN Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, AGRX is priced at $1.51, while HLN trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HLN's P/E ratio is 22.81. In terms of profitability, AGRX's ROE is +0.93%, compared to HLN's ROE of +0.09%. Regarding short-term risk, AGRX is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check HLN's competition here
AGRX vs TEVA Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TEVA has a market cap of 19B. Regarding current trading prices, AGRX is priced at $1.51, while TEVA trades at $16.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TEVA's P/E ratio is -14.39. In terms of profitability, AGRX's ROE is +0.93%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, AGRX is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check TEVA's competition here
AGRX vs ITCI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AGRX is priced at $1.51, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AGRX's ROE is +0.93%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ITCI's competition here
AGRX vs NBIX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, NBIX has a market cap of 13.3B. Regarding current trading prices, AGRX is priced at $1.51, while NBIX trades at $134.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas NBIX's P/E ratio is 45.49. In terms of profitability, AGRX's ROE is +0.93%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, AGRX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check NBIX's competition here
AGRX vs RDY Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, RDY has a market cap of 12.3B. Regarding current trading prices, AGRX is priced at $1.51, while RDY trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RDY's P/E ratio is 18.68. In terms of profitability, AGRX's ROE is +0.93%, compared to RDY's ROE of +0.17%. Regarding short-term risk, AGRX is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check RDY's competition here
AGRX vs CTLT Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AGRX is priced at $1.51, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AGRX's ROE is +0.93%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, AGRX is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check CTLT's competition here
AGRX vs VTRS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, VTRS has a market cap of 10.8B. Regarding current trading prices, AGRX is priced at $1.51, while VTRS trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas VTRS's P/E ratio is -2.89. In terms of profitability, AGRX's ROE is +0.93%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, AGRX is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check VTRS's competition here
AGRX vs ELAN Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ELAN has a market cap of 7.1B. Regarding current trading prices, AGRX is priced at $1.51, while ELAN trades at $14.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ELAN's P/E ratio is 19.72. In terms of profitability, AGRX's ROE is +0.93%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ELAN's competition here
AGRX vs RGC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, RGC has a market cap of 6.9B. Regarding current trading prices, AGRX is priced at $1.51, while RGC trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RGC's P/E ratio is -1389.00. In terms of profitability, AGRX's ROE is +0.93%, compared to RGC's ROE of -0.50%. Regarding short-term risk, AGRX is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check RGC's competition here
AGRX vs LNTH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, AGRX is priced at $1.51, while LNTH trades at $72.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LNTH's P/E ratio is 20.75. In terms of profitability, AGRX's ROE is +0.93%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AGRX is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check LNTH's competition here
AGRX vs PRGO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PRGO has a market cap of 3.9B. Regarding current trading prices, AGRX is priced at $1.51, while PRGO trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PRGO's P/E ratio is -23.40. In terms of profitability, AGRX's ROE is +0.93%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, AGRX is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check PRGO's competition here
AGRX vs HCM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, HCM has a market cap of 3.4B. Regarding current trading prices, AGRX is priced at $1.51, while HCM trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HCM's P/E ratio is 96.05. In terms of profitability, AGRX's ROE is +0.93%, compared to HCM's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check HCM's competition here
AGRX vs ALVOW Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, AGRX is priced at $1.51, while ALVOW trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALVOW's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +0.93%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, AGRX is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ALVOW's competition here
AGRX vs ALVO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ALVO has a market cap of 2.9B. Regarding current trading prices, AGRX is priced at $1.51, while ALVO trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALVO's P/E ratio is 25.58. In terms of profitability, AGRX's ROE is +0.93%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, AGRX is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ALVO's competition here
AGRX vs AMRX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, AMRX has a market cap of 2.5B. Regarding current trading prices, AGRX is priced at $1.51, while AMRX trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AMRX's P/E ratio is -202.25. In terms of profitability, AGRX's ROE is +0.93%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check AMRX's competition here
AGRX vs BHC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, AGRX is priced at $1.51, while BHC trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BHC's P/E ratio is -56.88. In terms of profitability, AGRX's ROE is +0.93%, compared to BHC's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check BHC's competition here
AGRX vs DCPH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AGRX is priced at $1.51, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AGRX's ROE is +0.93%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, AGRX is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check DCPH's competition here
AGRX vs INDV Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, INDV has a market cap of 2.2B. Regarding current trading prices, AGRX is priced at $1.51, while INDV trades at $17.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas INDV's P/E ratio is -345.60. In terms of profitability, AGRX's ROE is +0.93%, compared to INDV's ROE of -0.01%. Regarding short-term risk, AGRX is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check INDV's competition here
AGRX vs EMBCV Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AGRX is priced at $1.51, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +0.93%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, AGRX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check EMBCV's competition here
AGRX vs SUPN Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, AGRX is priced at $1.51, while SUPN trades at $33.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SUPN's P/E ratio is 30.14. In terms of profitability, AGRX's ROE is +0.93%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SUPN's competition here
AGRX vs BGM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BGM has a market cap of 1.9B. Regarding current trading prices, AGRX is priced at $1.51, while BGM trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BGM's P/E ratio is -32.10. In terms of profitability, AGRX's ROE is +0.93%, compared to BGM's ROE of -0.03%. Regarding short-term risk, AGRX is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check BGM's competition here
AGRX vs TARO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AGRX is priced at $1.51, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, AGRX's ROE is +0.93%, compared to TARO's ROE of +0.02%. Regarding short-term risk, AGRX is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check TARO's competition here
AGRX vs EVO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, AGRX is priced at $1.51, while EVO trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EVO's P/E ratio is -6.14. In terms of profitability, AGRX's ROE is +0.93%, compared to EVO's ROE of -0.22%. Regarding short-term risk, AGRX is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check EVO's competition here
AGRX vs ANIP Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, AGRX is priced at $1.51, while ANIP trades at $64.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ANIP's P/E ratio is -55.34. In terms of profitability, AGRX's ROE is +0.93%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, AGRX is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ANIP's competition here
AGRX vs DVAX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, AGRX is priced at $1.51, while DVAX trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DVAX's P/E ratio is -22.38. In terms of profitability, AGRX's ROE is +0.93%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AGRX is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check DVAX's competition here
AGRX vs HROW Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, AGRX is priced at $1.51, while HROW trades at $34.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HROW's P/E ratio is -56.61. In terms of profitability, AGRX's ROE is +0.93%, compared to HROW's ROE of -0.36%. Regarding short-term risk, AGRX is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check HROW's competition here
AGRX vs FLXN Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, AGRX is priced at $1.51, while FLXN trades at $25.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas FLXN's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +0.93%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, AGRX is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check FLXN's competition here
AGRX vs PAHC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PAHC has a market cap of 1.1B. Regarding current trading prices, AGRX is priced at $1.51, while PAHC trades at $28.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PAHC's P/E ratio is 35.91. In terms of profitability, AGRX's ROE is +0.93%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, AGRX is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check PAHC's competition here
AGRX vs AVDL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, AVDL has a market cap of 1B. Regarding current trading prices, AGRX is priced at $1.51, while AVDL trades at $10.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AVDL's P/E ratio is -40.88. In terms of profitability, AGRX's ROE is +0.93%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, AGRX is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check AVDL's competition here
AGRX vs AMPH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, AGRX is priced at $1.51, while AMPH trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AMPH's P/E ratio is 7.91. In terms of profitability, AGRX's ROE is +0.93%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, AGRX is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check AMPH's competition here
AGRX vs COLL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, COLL has a market cap of 1B. Regarding current trading prices, AGRX is priced at $1.51, while COLL trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas COLL's P/E ratio is 26.01. In terms of profitability, AGRX's ROE is +0.93%, compared to COLL's ROE of +0.19%. Regarding short-term risk, AGRX is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check COLL's competition here
AGRX vs PCRX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, AGRX is priced at $1.51, while PCRX trades at $21.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PCRX's P/E ratio is -9.65. In terms of profitability, AGRX's ROE is +0.93%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, AGRX is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check PCRX's competition here
AGRX vs PETQ Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AGRX is priced at $1.51, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AGRX's ROE is +0.93%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check PETQ's competition here
AGRX vs CRON Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CRON has a market cap of 774.7M. Regarding current trading prices, AGRX is priced at $1.51, while CRON trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CRON's P/E ratio is 14.36. In terms of profitability, AGRX's ROE is +0.93%, compared to CRON's ROE of +0.05%. Regarding short-term risk, AGRX is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check CRON's competition here
AGRX vs EMBC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EMBC has a market cap of 628.3M. Regarding current trading prices, AGRX is priced at $1.51, while EMBC trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EMBC's P/E ratio is 12.08. In terms of profitability, AGRX's ROE is +0.93%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, AGRX is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check EMBC's competition here
AGRX vs ORGO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ORGO has a market cap of 605.1M. Regarding current trading prices, AGRX is priced at $1.51, while ORGO trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ORGO's P/E ratio is -29.81. In terms of profitability, AGRX's ROE is +0.93%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, AGRX is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ORGO's competition here
AGRX vs TLRY Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TLRY has a market cap of 598.9M. Regarding current trading prices, AGRX is priced at $1.51, while TLRY trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TLRY's P/E ratio is -0.52. In terms of profitability, AGRX's ROE is +0.93%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, AGRX is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check TLRY's competition here
AGRX vs EOLS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EOLS has a market cap of 596.4M. Regarding current trading prices, AGRX is priced at $1.51, while EOLS trades at $9.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EOLS's P/E ratio is -10.39. In terms of profitability, AGRX's ROE is +0.93%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, AGRX is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check EOLS's competition here
AGRX vs BDSI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AGRX is priced at $1.51, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AGRX's ROE is +0.93%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AGRX is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check BDSI's competition here
AGRX vs SIGA Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SIGA has a market cap of 500.8M. Regarding current trading prices, AGRX is priced at $1.51, while SIGA trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SIGA's P/E ratio is 10.46. In terms of profitability, AGRX's ROE is +0.93%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, AGRX is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SIGA's competition here
AGRX vs KMDA Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, KMDA has a market cap of 431.9M. Regarding current trading prices, AGRX is priced at $1.51, while KMDA trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas KMDA's P/E ratio is 26.82. In terms of profitability, AGRX's ROE is +0.93%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, AGRX is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check KMDA's competition here
AGRX vs AQST Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, AQST has a market cap of 390.4M. Regarding current trading prices, AGRX is priced at $1.51, while AQST trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AQST's P/E ratio is -7.02. In terms of profitability, AGRX's ROE is +0.93%, compared to AQST's ROE of +1.07%. Regarding short-term risk, AGRX is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check AQST's competition here
AGRX vs SNDL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SNDL has a market cap of 375.7M. Regarding current trading prices, AGRX is priced at $1.51, while SNDL trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SNDL's P/E ratio is -4.87. In terms of profitability, AGRX's ROE is +0.93%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, AGRX is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SNDL's competition here
AGRX vs EBS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EBS has a market cap of 352.8M. Regarding current trading prices, AGRX is priced at $1.51, while EBS trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EBS's P/E ratio is -2.52. In terms of profitability, AGRX's ROE is +0.93%, compared to EBS's ROE of -0.27%. Regarding short-term risk, AGRX is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check EBS's competition here
AGRX vs ALIM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AGRX is priced at $1.51, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AGRX's ROE is +0.93%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, AGRX is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ALIM's competition here
AGRX vs ESPR Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ESPR has a market cap of 291.4M. Regarding current trading prices, AGRX is priced at $1.51, while ESPR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ESPR's P/E ratio is -1.73. In terms of profitability, AGRX's ROE is +0.93%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, AGRX is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ESPR's competition here
AGRX vs LFCR Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, LFCR has a market cap of 267.3M. Regarding current trading prices, AGRX is priced at $1.51, while LFCR trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LFCR's P/E ratio is -4.91. In terms of profitability, AGRX's ROE is +0.93%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, AGRX is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check LFCR's competition here
AGRX vs ZYBT Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ZYBT has a market cap of 265.3M. Regarding current trading prices, AGRX is priced at $1.51, while ZYBT trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZYBT's P/E ratio is 186.60. In terms of profitability, AGRX's ROE is +0.93%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, AGRX is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ZYBT's competition here
AGRX vs LNDC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AGRX is priced at $1.51, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AGRX's ROE is +0.93%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, AGRX is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check LNDC's competition here
AGRX vs TKNO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TKNO has a market cap of 256M. Regarding current trading prices, AGRX is priced at $1.51, while TKNO trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TKNO's P/E ratio is -10.41. In terms of profitability, AGRX's ROE is +0.93%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, AGRX is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check TKNO's competition here
AGRX vs ACB Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ACB has a market cap of 249.7M. Regarding current trading prices, AGRX is priced at $1.51, while ACB trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ACB's P/E ratio is 20.18. In terms of profitability, AGRX's ROE is +0.93%, compared to ACB's ROE of +0.00%. Regarding short-term risk, AGRX is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ACB's competition here
AGRX vs TYHT Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AGRX is priced at $1.51, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AGRX's ROE is +0.93%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, AGRX is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check TYHT's competition here
AGRX vs CGC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CGC has a market cap of 211.8M. Regarding current trading prices, AGRX is priced at $1.51, while CGC trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CGC's P/E ratio is -0.25. In terms of profitability, AGRX's ROE is +0.93%, compared to CGC's ROE of -1.13%. Regarding short-term risk, AGRX is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check CGC's competition here
AGRX vs OGI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, OGI has a market cap of 188.8M. Regarding current trading prices, AGRX is priced at $1.51, while OGI trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas OGI's P/E ratio is 10.85. In terms of profitability, AGRX's ROE is +0.93%, compared to OGI's ROE of +0.05%. Regarding short-term risk, AGRX is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check OGI's competition here
AGRX vs SXTC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SXTC has a market cap of 179.8M. Regarding current trading prices, AGRX is priced at $1.51, while SXTC trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SXTC's P/E ratio is 0.01. In terms of profitability, AGRX's ROE is +0.93%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, AGRX is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check SXTC's competition here
AGRX vs REPH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AGRX is priced at $1.51, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, AGRX's ROE is +0.93%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AGRX is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check REPH's competition here
AGRX vs DERM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, DERM has a market cap of 176.8M. Regarding current trading prices, AGRX is priced at $1.51, while DERM trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DERM's P/E ratio is -20.51. In terms of profitability, AGRX's ROE is +0.93%, compared to DERM's ROE of -0.52%. Regarding short-term risk, AGRX is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check DERM's competition here
AGRX vs BIOA Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BIOA has a market cap of 160.6M. Regarding current trading prices, AGRX is priced at $1.51, while BIOA trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BIOA's P/E ratio is -2.31. In terms of profitability, AGRX's ROE is +0.93%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, AGRX is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check BIOA's competition here
AGRX vs THTX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, THTX has a market cap of 145.3M. Regarding current trading prices, AGRX is priced at $1.51, while THTX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas THTX's P/E ratio is -16.63. In terms of profitability, AGRX's ROE is +0.93%, compared to THTX's ROE of +0.38%. Regarding short-term risk, AGRX is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check THTX's competition here
AGRX vs IRWD Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, IRWD has a market cap of 144M. Regarding current trading prices, AGRX is priced at $1.51, while IRWD trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas IRWD's P/E ratio is -4.68. In terms of profitability, AGRX's ROE is +0.93%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, AGRX is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check IRWD's competition here
AGRX vs CRDL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CRDL has a market cap of 120.7M. Regarding current trading prices, AGRX is priced at $1.51, while CRDL trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CRDL's P/E ratio is -4.17. In terms of profitability, AGRX's ROE is +0.93%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, AGRX is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check CRDL's competition here
AGRX vs SCTL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AGRX is priced at $1.51, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AGRX's ROE is +0.93%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AGRX is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SCTL's competition here
AGRX vs PROC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, AGRX is priced at $1.51, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, AGRX's ROE is +0.93%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AGRX is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check PROC's competition here
AGRX vs IXHL Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, IXHL has a market cap of 100.3M. Regarding current trading prices, AGRX is priced at $1.51, while IXHL trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas IXHL's P/E ratio is -0.87. In terms of profitability, AGRX's ROE is +0.93%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, AGRX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check IXHL's competition here
AGRX vs OPTN Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AGRX is priced at $1.51, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AGRX's ROE is +0.93%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, AGRX is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check OPTN's competition here
AGRX vs ZOM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AGRX is priced at $1.51, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AGRX's ROE is +0.93%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, AGRX is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ZOM's competition here
AGRX vs GRVI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AGRX is priced at $1.51, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AGRX's ROE is +0.93%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, AGRX is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check GRVI's competition here
AGRX vs INCR Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, INCR has a market cap of 81.8M. Regarding current trading prices, AGRX is priced at $1.51, while INCR trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas INCR's P/E ratio is -3.33. In terms of profitability, AGRX's ROE is +0.93%, compared to INCR's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check INCR's competition here
AGRX vs QNTM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, QNTM has a market cap of 76.8M. Regarding current trading prices, AGRX is priced at $1.51, while QNTM trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas QNTM's P/E ratio is -1.70. In terms of profitability, AGRX's ROE is +0.93%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, AGRX is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check QNTM's competition here
AGRX vs ZYNE Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AGRX is priced at $1.51, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AGRX's ROE is +0.93%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AGRX is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ZYNE's competition here
AGRX vs ASRT Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ASRT has a market cap of 68.1M. Regarding current trading prices, AGRX is priced at $1.51, while ASRT trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ASRT's P/E ratio is -2.22. In terms of profitability, AGRX's ROE is +0.93%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, AGRX is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check ASRT's competition here
AGRX vs SSIC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AGRX is priced at $1.51, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AGRX's ROE is +0.93%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, AGRX is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SSIC's competition here
AGRX vs VLNS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AGRX is priced at $1.51, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AGRX's ROE is +0.93%, compared to VLNS's ROE of N/A. Regarding short-term risk, AGRX is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check VLNS's competition here
AGRX vs DRRX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, DRRX has a market cap of 58.4M. Regarding current trading prices, AGRX is priced at $1.51, while DRRX trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas DRRX's P/E ratio is -3.92. In terms of profitability, AGRX's ROE is +0.93%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, AGRX is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check DRRX's competition here
AGRX vs KALA Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, KALA has a market cap of 54.2M. Regarding current trading prices, AGRX is priced at $1.51, while KALA trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas KALA's P/E ratio is -1.14. In terms of profitability, AGRX's ROE is +0.93%, compared to KALA's ROE of -3.69%. Regarding short-term risk, AGRX is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check KALA's competition here
AGRX vs CPIX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CPIX has a market cap of 52.2M. Regarding current trading prices, AGRX is priced at $1.51, while CPIX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CPIX's P/E ratio is -14.54. In terms of profitability, AGRX's ROE is +0.93%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, AGRX is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check CPIX's competition here
AGRX vs JUPW Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AGRX is priced at $1.51, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AGRX's ROE is +0.93%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, AGRX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check JUPW's competition here
AGRX vs EGRX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, EGRX has a market cap of 47.9M. Regarding current trading prices, AGRX is priced at $1.51, while EGRX trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas EGRX's P/E ratio is 4.34. In terms of profitability, AGRX's ROE is +0.93%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, AGRX is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check EGRX's competition here
AGRX vs QLI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AGRX is priced at $1.51, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, AGRX's ROE is +0.93%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AGRX is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check QLI's competition here
AGRX vs RMTI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, RMTI has a market cap of 34.9M. Regarding current trading prices, AGRX is priced at $1.51, while RMTI trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas RMTI's P/E ratio is -102.00. In terms of profitability, AGRX's ROE is +0.93%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, AGRX is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check RMTI's competition here
AGRX vs HEXO Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AGRX is priced at $1.51, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AGRX's ROE is +0.93%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AGRX is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check HEXO's competition here
AGRX vs SCYX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, AGRX is priced at $1.51, while SCYX trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SCYX's P/E ratio is -1.27. In terms of profitability, AGRX's ROE is +0.93%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, AGRX is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check SCYX's competition here
AGRX vs COSM Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, COSM has a market cap of 24.5M. Regarding current trading prices, AGRX is priced at $1.51, while COSM trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas COSM's P/E ratio is -0.77. In terms of profitability, AGRX's ROE is +0.93%, compared to COSM's ROE of -0.51%. Regarding short-term risk, AGRX is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check COSM's competition here
AGRX vs CYTH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AGRX is priced at $1.51, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AGRX's ROE is +0.93%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, AGRX is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check CYTH's competition here
AGRX vs GELS Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, GELS has a market cap of 18.8M. Regarding current trading prices, AGRX is priced at $1.51, while GELS trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas GELS's P/E ratio is -5.36. In terms of profitability, AGRX's ROE is +0.93%, compared to GELS's ROE of -0.07%. Regarding short-term risk, AGRX is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for AGRX.Check GELS's competition here
AGRX vs AYTU Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, AYTU has a market cap of 15.7M. Regarding current trading prices, AGRX is priced at $1.51, while AYTU trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas AYTU's P/E ratio is -1.70. In terms of profitability, AGRX's ROE is +0.93%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, AGRX is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check AYTU's competition here
AGRX vs FLGC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, FLGC has a market cap of 14.7M. Regarding current trading prices, AGRX is priced at $1.51, while FLGC trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas FLGC's P/E ratio is -0.68. In terms of profitability, AGRX's ROE is +0.93%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, AGRX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check FLGC's competition here
AGRX vs ACRX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AGRX is priced at $1.51, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AGRX's ROE is +0.93%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, AGRX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check ACRX's competition here
AGRX vs PRPH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, PRPH has a market cap of 14.6M. Regarding current trading prices, AGRX is priced at $1.51, while PRPH trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas PRPH's P/E ratio is -0.16. In terms of profitability, AGRX's ROE is +0.93%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, AGRX is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check PRPH's competition here
AGRX vs TXMD Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TXMD has a market cap of 13.4M. Regarding current trading prices, AGRX is priced at $1.51, while TXMD trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TXMD's P/E ratio is -6.11. In terms of profitability, AGRX's ROE is +0.93%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, AGRX is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check TXMD's competition here
AGRX vs BFRI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BFRI has a market cap of 10.6M. Regarding current trading prices, AGRX is priced at $1.51, while BFRI trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BFRI's P/E ratio is -1.30. In terms of profitability, AGRX's ROE is +0.93%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, AGRX is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check BFRI's competition here
AGRX vs BFRIW Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, BFRIW has a market cap of 10.3M. Regarding current trading prices, AGRX is priced at $1.51, while BFRIW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas BFRIW's P/E ratio is -0.14. In terms of profitability, AGRX's ROE is +0.93%, compared to BFRIW's ROE of -2.16%. Regarding short-term risk, AGRX is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check BFRIW's competition here
AGRX vs SISI Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, SISI has a market cap of 9.8M. Regarding current trading prices, AGRX is priced at $1.51, while SISI trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas SISI's P/E ratio is N/A. In terms of profitability, AGRX's ROE is +0.93%, compared to SISI's ROE of -1.41%. Regarding short-term risk, AGRX is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check SISI's competition here
AGRX vs TLPH Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, TLPH has a market cap of 9.1M. Regarding current trading prices, AGRX is priced at $1.51, while TLPH trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas TLPH's P/E ratio is -1.01. In terms of profitability, AGRX's ROE is +0.93%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, AGRX is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check TLPH's competition here
AGRX vs IMCC Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, IMCC has a market cap of 8.2M. Regarding current trading prices, AGRX is priced at $1.51, while IMCC trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas IMCC's P/E ratio is -1.92. In terms of profitability, AGRX's ROE is +0.93%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, AGRX is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check IMCC's competition here
AGRX vs NLTX Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AGRX is priced at $1.51, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AGRX's ROE is +0.93%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, AGRX is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check NLTX's competition here
AGRX vs YCBD Comparison July 2025
AGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGRX stands at 10.4M. In comparison, YCBD has a market cap of 7.9M. Regarding current trading prices, AGRX is priced at $1.51, while YCBD trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGRX currently has a P/E ratio of -0.89, whereas YCBD's P/E ratio is 0.01. In terms of profitability, AGRX's ROE is +0.93%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, AGRX is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for AGRX.Check YCBD's competition here